Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
56
CSTL Quote, Financials, Valuation and Earnings
Last price:
$39.39
Seasonality move
:
-8.42%
Day range:
$39.28 - $39.97
52-week range:
$14.59 - $42.18
Dividend yield:
0%
P/E ratio:
30.24x
P/S ratio:
3.37x
P/B ratio:
2.46x
Volume:
187K
Avg. volume:
418.2K
1-year change:
45.37%
Market cap:
$1.1B
Revenue:
$332.1M
EPS (TTM):
-$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$71.1M | -$0.51 | -11.48% | -26.99% | $40.38 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 21.97% | 68.6% | $109.25 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
CTSO
CytoSorbents Corp.
|
$10M | -$0.07 | 51.05% | -41.38% | $4.92 |
|
DCTH
Delcath Systems, Inc.
|
$25.3M | -$0.09 | 32.37% | -69.37% | $22.31 |
|
STRR
Star Operating Cos., Inc.
|
$16.8M | -$0.76 | 50.04% | -65.48% | $12.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$39.40 | $40.38 | $1.1B | 30.24x | $0.00 | 0% | 3.37x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$82.41 | $109.25 | $1.9B | 50.54x | $0.00 | 0% | 2.02x |
|
CRMD
CorMedix, Inc.
|
$12.53 | $19.00 | $987.2M | 6.10x | $0.00 | 0% | 4.22x |
|
CTSO
CytoSorbents Corp.
|
$0.68 | $4.92 | $42.7M | -- | $0.00 | 0% | 1.21x |
|
DCTH
Delcath Systems, Inc.
|
$10.30 | $22.31 | $363.7M | 1,183.91x | $0.00 | 0% | 4.91x |
|
STRR
Star Operating Cos., Inc.
|
$10.92 | $12.00 | $37.5M | 0.75x | $0.00 | 0% | 0.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
7.37% | 1.094 | 5.59% | 6.09x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
CTSO
CytoSorbents Corp.
|
75.25% | 1.075 | 46.74% | 1.49x |
|
DCTH
Delcath Systems, Inc.
|
0.83% | 1.825 | 0.25% | 12.82x |
|
STRR
Star Operating Cos., Inc.
|
26.85% | 8.871 | 70.75% | 0.76x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$61.5M | -$6.8M | -2.54% | -2.71% | -8.19% | $7.8M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
CTSO
CytoSorbents Corp.
|
$6.7M | -$2.7M | -27.15% | -89.32% | -28.07% | -$2.5M |
|
DCTH
Delcath Systems, Inc.
|
$17.9M | -$388K | 1.56% | 1.59% | -1.89% | $4.3M |
|
STRR
Star Operating Cos., Inc.
|
$5.6M | -$866K | -2.74% | -3.67% | -3.65% | -$2.4M |
Castle Biosciences, Inc. vs. Competitors
-
Which has Higher Returns CSTL or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 10.59%. Castle Biosciences, Inc.'s return on equity of -2.71% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About CSTL or ANIP?
Castle Biosciences, Inc. has a consensus price target of $40.38, signalling upside risk potential of 2.49%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 32.57%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is CSTL or ANIP More Risky?
Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.
-
Which is a Better Dividend Stock CSTL or ANIP?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSTL or ANIP?
Castle Biosciences, Inc. quarterly revenues are $83M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Castle Biosciences, Inc.'s net income of -$501K is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while ANI Pharmaceuticals, Inc.'s PE ratio is 50.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.37x versus 2.02x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.37x 30.24x $83M -$501K ANIPANI Pharmaceuticals, Inc.2.02x 50.54x $227.8M $24.1M
-
Which has Higher Returns CSTL or CRMD?
CorMedix, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 49.9%. Castle Biosciences, Inc.'s return on equity of -2.71% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About CSTL or CRMD?
Castle Biosciences, Inc. has a consensus price target of $40.38, signalling upside risk potential of 2.49%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 51.64%. Given that CorMedix, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe CorMedix, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 CRMDCorMedix, Inc.4 0 0 -
Is CSTL or CRMD More Risky?
Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock CSTL or CRMD?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or CRMD?
Castle Biosciences, Inc. quarterly revenues are $83M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Castle Biosciences, Inc.'s net income of -$501K is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while CorMedix, Inc.'s PE ratio is 6.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.37x versus 4.22x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.37x 30.24x $83M -$501K CRMDCorMedix, Inc.4.22x 6.10x $104.3M $108.6M
-
Which has Higher Returns CSTL or CTSO?
CytoSorbents Corp. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of -33.42%. Castle Biosciences, Inc.'s return on equity of -2.71% beat CytoSorbents Corp.'s return on equity of -89.32%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M CTSOCytoSorbents Corp.70.28% -$0.05 $36.4M -
What do Analysts Say About CSTL or CTSO?
Castle Biosciences, Inc. has a consensus price target of $40.38, signalling upside risk potential of 2.49%. On the other hand CytoSorbents Corp. has an analysts' consensus of $4.92 which suggests that it could grow by 623.04%. Given that CytoSorbents Corp. has higher upside potential than Castle Biosciences, Inc., analysts believe CytoSorbents Corp. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 CTSOCytoSorbents Corp.1 1 0 -
Is CSTL or CTSO More Risky?
Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison CytoSorbents Corp. has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.454%.
-
Which is a Better Dividend Stock CSTL or CTSO?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. CytoSorbents Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or CTSO?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than CytoSorbents Corp. quarterly revenues of $9.5M. Castle Biosciences, Inc.'s net income of -$501K is higher than CytoSorbents Corp.'s net income of -$3.2M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while CytoSorbents Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.37x versus 1.21x for CytoSorbents Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.37x 30.24x $83M -$501K CTSOCytoSorbents Corp.1.21x -- $9.5M -$3.2M
-
Which has Higher Returns CSTL or DCTH?
Delcath Systems, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 4.04%. Castle Biosciences, Inc.'s return on equity of -2.71% beat Delcath Systems, Inc.'s return on equity of 1.59%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M DCTHDelcath Systems, Inc.87.24% $0.02 $115.8M -
What do Analysts Say About CSTL or DCTH?
Castle Biosciences, Inc. has a consensus price target of $40.38, signalling upside risk potential of 2.49%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.31 which suggests that it could grow by 116.55%. Given that Delcath Systems, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Delcath Systems, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 DCTHDelcath Systems, Inc.5 0 0 -
Is CSTL or DCTH More Risky?
Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.033%.
-
Which is a Better Dividend Stock CSTL or DCTH?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or DCTH?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.6M. Castle Biosciences, Inc.'s net income of -$501K is lower than Delcath Systems, Inc.'s net income of $830K. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Delcath Systems, Inc.'s PE ratio is 1,183.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.37x versus 4.91x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.37x 30.24x $83M -$501K DCTHDelcath Systems, Inc.4.91x 1,183.91x $20.6M $830K
-
Which has Higher Returns CSTL or STRR?
Star Operating Cos., Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 14.56%. Castle Biosciences, Inc.'s return on equity of -2.71% beat Star Operating Cos., Inc.'s return on equity of -3.67%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M STRRStar Operating Cos., Inc.23.43% $0.86 $85.6M -
What do Analysts Say About CSTL or STRR?
Castle Biosciences, Inc. has a consensus price target of $40.38, signalling upside risk potential of 2.49%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 9.89%. Given that Star Operating Cos., Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Star Operating Cos., Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 STRRStar Operating Cos., Inc.1 1 0 -
Is CSTL or STRR More Risky?
Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.714, suggesting its more volatile than the S&P 500 by 171.399%.
-
Which is a Better Dividend Stock CSTL or STRR?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Star Operating Cos., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSTL or STRR?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than Star Operating Cos., Inc. quarterly revenues of $23.7M. Castle Biosciences, Inc.'s net income of -$501K is lower than Star Operating Cos., Inc.'s net income of $3.5M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.37x versus 0.52x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.37x 30.24x $83M -$501K STRRStar Operating Cos., Inc.0.52x 0.75x $23.7M $3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
